BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31

BioNexus Gene Lab Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.23+0.03 (+2.23%)

Close on Oct 19, 2026

Market cap: $2.97M
P/E (TTM): –
Dividend yield: –

BioNexus Gene Lab Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	7.42	9.51	9.77	11	13	11	0.13	0.21
Cost of Revenue	6.34	8.22	8.44	9.67	11	9.67	0.07	-0.18
Gross Profit	1.09	1.29	1.33	1.26	2.27	1.72	0.06	0.03
Research & Development	0.05	0.05	0.05	–	–	–	–	–
Selling, General & Admin	3.27	3.86	3.04	–	–	–	–	–
Selling & Marketing	1.74	2.03	0.60	–	–	–	–	–
General & Administrative	1.54	1.83	2.44	1.73	1.28	1.33	0.36	-0.24
Operating Expenses	4.48	4.94	-4.41	–	–	–	–	–
Operating Income	-2.97	-1.57	-2.59	-0.29	1.06	1.27	-0.28	0.06
Interest Expense	–	–	0.01	0.01	–	–	–	–
Interest & Investment Income	0.08	0.15	0.07	–	–	-0.01	–	–
Other Non-Operating Income	0.43	2.07	0.49	–	–	–	0.03	-0.03
Gain (Loss) on Investments	0	0.07	0.31	–	0	0.00	0	–
Gain (Loss) on Sale of Assets	–	–	-0.03	0	-0.01	-0.03	0	–
Pretax Income	-2.98	-1.59	-2.61	-0.30	1.04	–	–	–
Income Tax Expense	0	0.00	-0.02	-0.05	-0.29	–	0.02	-0.03
Net Income incl. Noncontrolling Interests	-2.98	-1.60	2.63	-0.36	0.75	1.09	-0.25	0.03
Net Income	-2.98	-1.60	-2.63	-0.36	0.75	1.09	-0.25	0.03
Net Income to Common	-2.98	-1.60	-2.63	–	–	–	-0.25	–
EPS (Basic)(per share)	–	–	–	–	–	0.01	0.00	0.00
EPS (Diluted)(per share)	–	-0.09	-0.17	–	–	0.01	0.00	0.00
Shares Outstanding (Basic, Weighted)(shares)	–	–	–	–	–	103	86	66
Shares Outstanding (Diluted, Weighted)(shares)	–	18	16	–	–	103	86	66
EBITDA	–	–	–	–	–	–	-0.23	0.10
Net Interest Income	–	–	0.01	0.01	–	–	–	–
Provision for Credit Losses	-0.27	-0.88	-1.31	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 12.3%
Operating margin: -81.8%
Net margin: -82.4%
Return on equity, FY2025: -35.2%

Financial strength

Current ratio: 6.08
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 151.6%

Valuation

P/E ratio: –
Price to sales: 0.95
Price to book: 0.38
Dividend yield: –